Latest News

Treatment With Tralokinumab Improved Epidermal Pathology, Reduced Systemic Markers In Type 2 Inflammation
Treatment With Tralokinumab Improved Epidermal Pathology, Reduced Systemic Markers In Type 2 Inflammation

April 12th 2024

Treatment also shifted the expression of key biomarkers in atopic dermatitis toward non-lesional levels, according to a recent study.

Probiotics Cannot Replace Standard of Care Atopic Dermatitis Therapies, Research Letter Argues
Probiotics Cannot Replace Standard of Care Atopic Dermatitis Therapies, Research Letter Argues

April 11th 2024

Countdown to RAVE!
Countdown to RAVE!

April 5th 2024

Managing Mental Health Comorbidities in Adult Patients With Atopic Dermatitis
Managing Mental Health Comorbidities in Adult Patients With Atopic Dermatitis

April 5th 2024

Dupilumab Shows Superiority in Reducing Upper Respiratory Infections in Patients With AD
Dupilumab Shows Superiority in Reducing Upper Respiratory Infections in Patients With AD

April 4th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.